|
|
Received: 30 December 2020
|
|
|
|
|
[1] |
Tung A, Maliniak K, Tenicela R, et al. Intrathecal morphine for intraoperative and postoperative analgesia[J].JAMA,1980, 244(23):2637-2638.
|
[2] |
Timothy R, Jason E, Salim Hayek, et al. The Polyanalgesic Consensus Conference (PACC): Recommendations on Intrathecal Drug Infusion Systems Best Practices and Guidelines[J]. Neuromodulation,2017,20(4):405-406.
|
[3] |
蔡昀方,刘波涛,王 稳,等. 置入式鞘内镇痛泵因电池耗竭更换新泵1例[J]. 中国疼痛医学杂志,2019,25(6):476-477.
|
[4] |
刘楹子,杨晓秋. 鞘内镇痛在难治性疼痛治疗中的应用[J]. 中国疼痛医学杂志,2019,25(1):50-56.
|
[5] |
裴爱杰,过建国,冯智英. 影响置入性鞘内药物输注系统治疗慢性疼痛疗效的研究进展[J]. 国际麻醉学与复苏杂志,2017,38(1):70-75.
|
[6] |
毛 鹏,郑春英,樊碧发. 可置入鞘内药物输注系统置换术后出现吗啡戒断症状1例[J]. 中国疼痛医学杂志,2019,25(11):879-880.
|
[7] |
Sommer B, Karageorgos N, AlSharif M, et al. Long-term outcome and adverse events of intrathecal opioid therapy for nonmalignant pain syndrome[J]. Pain Pract, 2020, 20(1):8-15.
|
[8] |
崔琦芬,汤士亚,陆晓刚,等. 右美托咪定复合罗哌卡因腹横肌平面阻滞的应用进展[J]. 武警医学,2021,32(3):259-261.
|
[9] |
Timothy R D, Jason E P, Michael C H, et al. Intrathecal therapy for chronic pain: a review of morphine and ziconotide as firstline options[J]. Pain Med, 2019, 20(4):784-798.
|
[10] |
Ying H, Xihan L, Tong Z, et al. Efficacy and safety of ropivacaine addition to intrathecal morphine for pain management in intractable cancer[J]. Mediat Inflamm, 2015,2015:439014.
|
[11] |
A Blanie, S Figueiredo, G Lorre, et al. Transient neurologic symptoms (tns) after intrathecal injection of ropivacaine through a dural tap during an attempted epidural for labour pain relief. anaesth crit[J]. Care Pain Med, 2017, 36(5):325-326.
|
[12] |
陈付强,封明霞,于 洋,等. 罗哌卡因对氢吗啡酮鞘内自控镇痛治疗难治性上腹部癌痛患者疗效的影响[J]. 中华疼痛学杂志,2020,12(2):112-118.
|
[13] |
Li H, Yang L, Guo Z, et al. Successful treatment of refractory cancer pain with morphine and ropivacaine: a case report[J]. Medicine (Baltimore), 2017,96(22):e7052.
|
[14] |
Flack S H, Anderson C M, Bernards C. Morphine distribution in the spinal cord after chronic infusion in pigs[J]. Anesth Analg, 2011,112(2):460-464.
|
|
|